The Tennis Anti-Doping Programme is a comprehensive and internationally-recognised programme that applies to all players who hold an ATP or WTA ranking, or who enter or compete in events organised, sanctioned or recognised by the ITF.
This includes Grand Slam tournaments, Davis Cup and Fed Cup ties, Olympic and Paralympic Tennis Events, ATP and WTA tournaments, ATP Challenger Tour tournaments, ITF Pro Circuit tournaments, ITF Junior events, ITF Seniors events, ITF Wheelchair events and ITF Beach Tennis Tour events.
The purposes of the Tennis Anti-Doping Programme are as follows:
- Maintain the integrity of tennis
- Protect the health and rights of all tennis players
The Tennis Anti-Doping Programme maintains a common set of rules and procedures that apply across all levels of tennis. Players are tested for banned substances in accordance with the prevailing version of the World Anti-Doping Agency’s Prohibited List. The Tennis Anti-Doping Programme is fully compliant with the World Anti-Doping Code.
The Programme began in 1993, with three governing bodies – the ITF, ATP and WTA Tour – managing testing at their own events, through the ITF at the independent Grand Slam tournaments, and dealing with any cases arising from their events. Out-of-competition testing was also conducted under the Tennis Anti-Doping Programme.
In 2011, the Programme conducted over 2,000 doping control tests, both in-competition and out-of-competition, and including both urine and blood samples.
Since 2006, the ITF has managed, administered and enforced the Tennis Anti-Doping Programme on behalf of the ATP, and on behalf of the WTA since 2007.
An out-of-competition testing programme has been conducted under the Tennis Anti-Doping Programme since 2005. This programme has been fully WADA Code-compliant since out-of-competition testing became mandatory in 2009. Players subject to this programme provide daily whereabouts information in order to permit effective no-notice out-of-competition testing.
If you have any general questions about the Tennis Anti-Doping Programme, please email the following address:
Enquiries relating to any particular substances, medications and/or Therapeutic Use Exemptions should be addressed to International Doping Tests and Management (IDTM):
Phone: +46 8 555 10 999
Fax: + 46 8 555 10 995
For further information please click here
Drug testing conducted by the Men’s Tennis Council began in the late 1980s and focused on recreational drugs.
- When the ATP Tour was formed in 1990, the governing body of the men’s professional tennis circuit extended the testing to include performance-enhancing drugs.
- The ITF and WTA Tour also had comprehensive anti-doping Programmes, and in 1993 the three bodies created a joint anti-doping Programme that covered the whole of tennis, including (through the ITF) the independent Grand Slam tournaments.
- In 2006 the ITF assumed responsibility for the management, administration and enforcement of the Programme at ATP-sanctioned events.
- In 2007 the ITF assumed responsibility for anti-doping matters at WTA-sanctioned events, leading to a unified Tennis Anti-Doping Programme applying across all tennis events.